Trial Profile
A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2066 Compared to Placebo in Peripheral Neuropathic Pain Patients With Mechanical Hypersensitivity.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2016
Price :
$35
*
At a glance
- Drugs AZD 2066 (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Acronyms NP-MH
- Sponsors AstraZeneca
- 31 Aug 2012 Results presented at the 14th World Congress on Pain.
- 28 Aug 2012 Primary endpoint 'Pain-intensity' has been met, based on results presented at 14th World Congress on Pain. However, due to termination of the study for safety reasons, only 87 of the planned 385 patients were enrolled.
- 28 Aug 2012 Primary endpoint 'Numerical-Rating-Scale' has been met, based on results presented at 14th World Congress on Pain. However, due to termination of the study for safety reasons, only 87 of the planned 385 patients were enrolled.